Related Experiment Videos
Single daily dose ceftriaxone therapy in epiglottitis
G J Knight1, M A Harris, M Parbari
1Mater Children's Hospital, South Brisbane, Queensland, Australia.
Insights
Single daily intravenous ceftriaxone effectively treated pediatric Haemophilus influenzae epiglottitis. This antibiotic demonstrated favorable outcomes, minimal side effects, and potential clinical and economic benefits for managing this serious infection.
Area of Science:
- Pediatric Infectious Diseases
- Bacteriology
- Pharmacology
Background:
- Epiglottitis is a severe upper airway infection primarily caused by Haemophilus influenzae.
- Prompt and effective antibiotic treatment is crucial for managing epiglottitis and preventing complications.
Purpose of the Study:
- To evaluate the efficacy and safety of ceftriaxone in treating pediatric patients with confirmed Haemophilus influenzae epiglottitis.
Main Methods:
- Seven pediatric patients with proven Haemophilus influenzae epiglottitis were treated.
- Treatment involved a single daily intravenous dose of ceftriaxone for five days.
- Serum drug levels and clinical responses were monitored.
Main Results:
- All seven children showed a favorable clinical response to ceftriaxone treatment.
- Achieved serum ceftriaxone levels significantly exceeded the minimum inhibitory concentration (MIC) against Haemophilus influenzae.
- Side effects were mild, transient, and did not necessitate treatment discontinuation.
Conclusions:
- Ceftriaxone is an effective and safe treatment option for pediatric Haemophilus influenzae epiglottitis.
- The drug's pharmacokinetic profile supports its use in a single daily dose regimen.
- Ceftriaxone presents potential clinical and economic advantages in epiglottitis management.
Abstract:
Ceftriaxone as a single daily intravenous dose for 5 days was used to treat seven patients with proven Haemophilus influenzae epiglottitis. All children responded favourably. The serum levels achieved exceeded the MIC by up to 1500 times at the trough level during and for up to 24 h after the completion of the treatment. Side effects were mild and transient and did not disrupt the continuity of the treatment. Ceftriaxone potentially offers a number of clinical and economic advantages in the management of epiglottitis.